hotspot -WSS

hotspot

author：focus 2025-09-10 05:03:25 - browse：65913

Obesity conference attendees with a pink and blue Wegovy sign hanging from the ceiling above. -- obesity coverage from STAT — Wegovy, the obesity drug, was inescapable at the ObesityWeek conference in Dallas. Elaine Chen

DALLAS — Here at ObesityWeek, one of the largest conferences on obesity, Novo Nordisk and Eli Lilly are displaying more than a dozen studies that together carry the message: Our blockbuster weight loss treatments will be worth it for society.

But experts point out that much of this company-funded research does not include the cost of the drugs themselves, which sell at more than $10,000 per year in the U.S. and are meant to be taken indefinitely.

The two major pharmaceutical companies have seen interest skyrocket for their GLP-1-based drugs like Ozempic, Wegovy, and Mounjaro, a new generation of medications that can cut substantial amounts of weight. But insurance plans have been slow to grant wide access to obesity treatments, concerned that the vast amount of people eligible to take them, along with their high price, could lead to significant financial strain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： AstraZeneca lung cancer study comes in below expectations

WSS

Artificial intelligence use in health care faces greater scrutiny in 2024

Use doctors trained outside the U.S. to ease the physician shortage

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

How Robert F. Kennedy Jr. distorted vaccine science

Undocumented workers face uncertainty as immigration law takes effect in Florida

Top Ukrainian generals say counteroffensive is 'going to plan' as losses mount

knowledge

hotspot

entertainment

Alkermes shareholders re

Resistance to opioid

What does generative AI mean for health care? We asked experts

Being 'nonadherent' patient made me a more empathetic doctor

As demand for Covid shots wanes, Moderna seeks its next success

Long Covid research funding gets a major boost from NIH

Sports medicine is finally prioritizing gender equality

Doctors on social media are being harassed and cyberbullied

State Dept. review finds Biden bears some blame for Afghanistan failures

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

focus

Artificial intelligence use in health care faces greater scrutiny in 2024

Artificial intelligence use in health care faces greater scrutiny in 2024

Having children helps parents live longer, especially after age 80

Bernie Sanders gets little from pharma CEOs on drug prices

STAT wants to know your pick for a great summer read or listen

AstraZeneca lung cancer study comes in below expectations

explore

leisure time

entertainment

focus